株探米国株
英語
エドガーで原本を確認する
0001835268false00018352682025-12-172025-12-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 17, 2025
________________________________________
Connect Biopharma Holdings Limited
(Exact name of Registrant as Specified in Its Charter)
________________________________________
Cayman Islands 001-40212 Not Applicable
(State or Other Jurisdiction
of Incorporation)		 (Commission File Number) (IRS Employer
Identification No.)
3580 Carmel Mountain Road, Suite 200
San Diego, California
 92130
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: (877) 245-2787
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
Symbol(s)		 Name of each exchange on which registered
Ordinary Shares, par value $0.000174 per Share CNTB The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o On December 17, 2025, Kan Chen, Ph.D., a partner at Qiming Venture Partners, notified Connect Biopharma Holdings Limited (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) and as a member of the Nominating and Corporate Governance Committee of the Board, effective immediately.


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Dr. Chen’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Chen indicated in his notice of resignation that, considering the Company’s recent successful strategic shift to become more U.S.-centric, including having a U.S.-based management team and conducting drug development work within the U.S. and Europe instead of in China, his contributions to the Company have enabled it for future growth and that now would be an appropriate time for him to resign from the Board.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CONNECT BIOPHARMA HOLDINGS LIMITED
Date: December 23, 2025 By: /s/ David Szekeres
Name: David Szekeres
Title: President